The Syneos Health Podcast
The Syneos Health Podcast Series dissects some of the most complex issues biopharma leaders are facing today. Our clinical and commercial experts provide time-tested solutions, as well as perspectives on the news of the day. Hosted by Jeff Stewart, a long-time industry consultant who has advised biopharma leaders on licensing, mergers and acquisitions, pricing and market access, commercialization and go-to-market strategies, each episode explores the challenges and considerations involved with bringing biopharmaceuticals to the market.
Episodes
149 episodes
Psychedelics 3.0: Challenges and Opportunities in an Evolving Field
There is a significant unmet need for medicines to treat neuropsychiatric and neurological conditions in underserved patient populations. Recently, there has been renewed interest in psychedelic, hallucinogenic and dissociative compounds to mee...
•
1:02:37
A Site-Specific Approach to Optimizing Diversity in Oncology Trials
As the biopharma industry strives to ensure that clinical trials reflect the rich diversity of the patient populations they aim to serve, the challenges to make this possible have fallen on the trial sites. In a recent webinar, Syne...
•
42:00
Circulating Tumor DNA: Transforming Oncology Clinical Trials
Use of circulating tumor DNA (ctDNA) – small fragments of DNA that are released into the bloodstream by cancer cells – as a diagnostic tool represents a significant shift toward more precise, personalized cancer care, enhancing both trial effic...
•
20:01
Cashing in on the Currency of Information
Medical science liaisons—or MSLs—within pharmaceutical companies deal in a special currency: scientific exchange and real-world insights gathering. Only they can share certain types of information with a growing number of medical stakeholders. ...
•
34:22
Decoding Gen AI’s Potential to Drive More Effective Clinical Trials
AI is seemingly everywhere now in our lives, including healthcare and drug discovery and development. AI certainly has the potential to enable major advances than development of more effective and safe medical products. And in fact, GenAI has a...
•
31:32
Connecting the Global Dots on Carbon Footprint in Biopharma
The World Economic Forum projects that by 2050, climate change could cause 14 million additional deaths and $12 trillion in global healthcare costs. And this will exacerbate global health inequities with our most vulnerable populations, includi...
•
27:16
Can AI Help Get the Right Patients Into Alzheimer's Clinical Trials?
Alzheimer's disease is a challenging and devastating diagnosis that affects memory and cognitive skills, with no known way to predict, track, treat, or cure it effectively. In 2024, around 90 million people over the age of 65 will be living wit...
•
31:58
Unpacking the Role of Adjuvant Therapies in Breast Cancer
Breast cancer is the most common type of cancer among women worldwide, and it can be treated with different modalities, such as surgery, chemotherapy, radiation, hormone therapy and targeted therapy. However, even after the primary treatment, s...
•
28:11
Site and Study Execution for Ophthalmology Trials
This is an exciting time in the development of new medicines to treat both rare and age-related eye diseases. But what is it like in the trenches to develop and deliver clinical trials that evaluate both the safety and efficacy of these potenti...
•
18:34
The Case for Genetic Medicines
In March 2024, the FDA approved a groundbreaking gene therapy for children with a specific form of leukodystrophy, offering hope to those with no current care options. However, the approval came with a hefty price tag, making headlines as the m...
•
32:02
Jeff Stewart Says Goodbye
After 7 years as the Syneos Health Podcast's founding and flagship host, Jeff Stewart is stepping down. Here, he reflects on his experience and bids farewell.It doesn't end here - stay tuned for new episodes with new host(s), coming soo...
•
4:31
Patient Assistance: The Best Deal in Pharma
Patient assistance programs can make a huge difference for patients who need expensive medicines but can't afford them. In this episode, Jeff Stewart talks with Dave MacLeod,...
•
29:10
Real Talk About the Inflation Reduction Act
The Inflation Reduction Act (IRA), signed into law by President Joe Biden in August 2022, brings significant changes to the U.S. pharmaceutical market as it rolls out over the next 10 years.Today we dive deep into the IRA with
•
28:39
Turbo-Charging Clinical Trials
For the first time, the technology behind Wall Street and Formula One racing is being used in pharmaceuticals—and it’s offering unparalleled potential for innovation in clinical trial execution and healthcare delivery.In this episode, h...
•
25:43
Investing for Commercial Success as an Emerging Company
When it comes to launching a pharmaceutical product in today’s market—especially as an emerging company—strategic investment can make all the difference.Drawing from a recent study on investing for commercial success,
•
20:08
Ophthalmology Clinical Trials: Low Vision and AMD Awareness Month
Age-related vision loss is a rising concern for our growing aging population. According to the most recent data published by the CDC, nearly 20 million Americans aged 40+ have been diagnosed with some form of age-related macular degeneration (A...
•
25:55
FDA Rules for Radio & TV Advertising
The FDA has finalized a rule that addresses how drug ads must be presented in TV and radio commercials. The rule, proposed in 2010 and now effective from May of this year, aims to provide clarity and guidelines for pharmaceutical companies in p...
•
19:27
2024 Health Trends: Managing the Healthcare Revolution
Nervousness and uncertainty surround the question of what Artificial Intelligence (AI) may mean for the future of work. How can we deploy AI transformation—thoughtfully—across an organization and help workforces see what the new models will sig...
•
16:59
World Mental Health Day: The State of Mental Health Clinical Development
October is National Depression and Mental Health Screening Month, with October 10th specifically recognized as World Mental Health Day. A recen...
•
24:21
Radiosensitizers in Head and Neck Cancer
Radiosensitizers have emerged as potential game-changers in head and neck cancer therapy. A diverse group of compounds, radiosensitizers enhance radiation therapy's impact on tumor cells. Ongoing research seeks radiosensitizers that augment rad...
•
14:14
Market Access for Weight Loss Drugs
One of the biggest trends making headlines and impacting the healthcare industry to date is the rising popularity of GLP-1 drugs. Initially developed for diabetes management, these products have recently gained traction for weight loss indicati...
•
21:06
Training MSLs in the Metaverse
In this episode of the Syneos Health Podcast, we embark on a journey into the metaverse – a revolutionary concept that's transforming the way we approach training and learning. As we delve into the world of the metaverse and its implica...
•
25:12
Biopharma and the Emergency Department
The emergency department (ER) can be a place of chaos, panic and infinite amounts of unpredictability. Not knowing what can come through the doors at any given time makes this environment impossible to foresee and prepare for. Because of ...
•
18:57